环孢素治疗激素难治性急性重症溃疡性结肠炎的长期疗效与安全性:ENEIDA登记研究(1989-2013)全国多中心队列
基于ENEIDA登记的多中心研究纳入740例激素难治性急性重症溃疡性结肠炎患者,其中377例接受环孢素、131例接受英夫利西单抗、63例接受序贯挽救治疗。环孢素组3个月和5年累积结肠切除率高于英夫利西单抗组,但2005年后治疗者两组早期和晚期结肠切除率无差异;环孢素组严重不良事件比例低于英夫利西单抗组和序贯治疗组,死亡率无差异。结论认为环孢素严重不良事件更少、疗效与英夫利西单抗相似,支持两者均可用于激素难治性急性重症溃疡性结肠炎。
要点
- 环孢素组3个月和5年累积结肠切除率24.1%,高于英夫利西单抗组14.5%(P=0.01)。
- 2005年后治疗者环孢素与英夫利西单抗的早期和晚期结肠切除率无差异。
- 环孢素组严重不良事件15.4%,低于英夫利西单抗组26.5%和序贯治疗组33.4%(P<0.001)。
核心结论
- 环孢素治疗激素难治性急性重症溃疡性结肠炎的严重不良事件率低于英夫利西单抗、疗效与英夫利西单抗相似,支持两者均可用于激素难治性急性重症溃疡性结肠炎。
- 序贯环孢素-英夫利西单抗用于环孢素无应答者的风险-获益可接受。
研究设计与样本
- 基于ENEIDA登记数据的多中心研究,纳入激素难治性急性重症溃疡性结肠炎患者740例,其中环孢素组377例、英夫利西单抗组131例、序贯挽救治疗组63例。
- 以英夫利西单抗或序贯挽救治疗(环孢素-英夫利西单抗或英夫利西单抗-环孢素)治疗的激素难治性急性重症溃疡性结肠炎患者作为对照。
主要发现
- 3个月和5年累积结肠切除率环孢素组24.1%、序贯治疗组32.7%,高于英夫利西单抗组14.5%(P=0.01)。
- 2005年后治疗的患者中,环孢素与英夫利西单抗的早期和晚期结肠切除率无差异。
- 接受环孢素治疗的患者中62%长期保持无结肠切除(中位71个月)。
- 死亡率环孢素组2.4%、英夫利西单抗组1.5%、序贯治疗组0%,组间无差异(P=0.771)。
- 严重不良事件比例环孢素组15.4%,低于英夫利西单抗组26.5%和序贯治疗组33.4%(P<0.001);仅分析2005年后治疗患者时该差异仍存在。
临床怎么用
- 作者结论认为环孢素严重不良事件率更低、疗效与英夫利西单抗相似,支持在激素难治性急性重症溃疡性结肠炎中使用环孢素或英夫利西单抗。
- 作者结论认为序贯环孢素-英夫利西单抗用于环孢素无应答者的风险-获益可接受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the efficacy and safety of cyclosporine (CyA) in a large national registry-based population of patients with steroid-refractory (SR) acute severe ulcerative colitis (ASUC) and to establish predictors of efficacy and adverse events. METHODS: Multicenter study of SR-ASUC treated with CyA, based on data from the ENEIDA registry. SR-ASUC patients treated with infliximab (IFX) or sequential rescue therapy (CyA-IFX or IFX-CyA) were used as comparators. RESULTS: Of 740 SR-ASUC patients, 377 received CyA, 131 IFX and 63 sequential rescue therapy. The cumulative colectomy rate was higher in the CyA (24.1%) and sequential therapy (32.7%) than in the IFX group (14.5%; P=0.01) at 3 months and 5 years. There were no differences in early and late colectomy between CyA and IFX in patients treated after 2005. 62% of patients receiving CyA remained colectomy-free in the long term (median 71 months). There were no differences in mortality between CyA (2.4%), IFX (1.5%) and sequential therapy (0%; P=0.771). The proportion of patients with serious adverse events (SAEs) was lower in CyA (15.4%) than in IFX treated patients (26.5%) or sequential therapy (33.4%; P<0.001). This difference in favor of CyA was maintained when only patients treated after 2005 were analyzed. CONCLUSIONS: Treatment with CyA showed a lower rate of SAE and a similar efficacy to that of IFX thereby supporting the use of either CyA or IFX in SR-ASUC. In addition, the risk-benefit of sequential CyA-IFX for CyA non-responders is acceptable.
引用
- Ordás I, Domènech E, Mañosa M, et al. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol. 2017. PMID: 28675163. doi:10.1038/ajg.2017.180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。